By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

MannKind Corporation 

28903 North Avenue Paine

Valencia  California  91355  U.S.A.
Phone: 661-775-5300 Fax: 661-775-2081


SEARCH JOBS

MannKind Corporation (Nasdaq:MNKD ) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, the Technosphere® Insulin System, is currently in Phase 3 clinical trials in the U.S., Europe and Latin America to study its safety and efficacy in the treatment of diabetes.

MannKind is focusing on three areas:

  • First, we are continuing to execute the Technosphere® Insulin clinical trial program.
  • Second, we are moving our second potential product – a therapeutic cancer vaccine – through Phase 1 clinical trials.
  • Third, we have begun clinical testing of the next product candidate for use with our Technosphere® platform technology.

    Our values, like our work, combine the vision of our founder with the pragmatism of the laboratory. Teamwork, communication, trust and respect sum up the way we work and the way we treat our colleagues, while accountability, quality, and execution motivate the results we achieve. Finally, integrity and enthusiasm describe the spirit we bring to our jobs.

    With around six hundred employees and three locations (in California, New Jersey, and Connecticut), we have grown significantly from our founding in 1991. We continue to be a tight-knit community where each of us has a critical role in our success. Committed to diversity, at MannKind we depend on a rich blend of ideas, backgrounds, and working styles in our quest to change the world for the better.

    Last Updated: 04-01-2008

    Key Statistics


    Email:
    Ownership: Public

    Web Site: MannKind Corporation
    Employees:
    Symbol: MNKD
     









  • Company News
    MannKind Corporation (MNKD) Reports 2014 Second Quarter Financial Results 8/11/2014 7:48:31 AM
    Sanofi (France) (SAN.PA) To Pay MannKind Corporation (MNKD) Up To $925 Million For Inhaled Insulin 8/11/2014 6:04:47 AM
    MannKind Corporation (MNKD) To Hold 2014 Second Quarter Financial Results Conference Call On August 11, 2014 8/5/2014 3:43:10 PM
    FDA Approves MannKind Corporation (MNKD)'s Much Anticipated Diabetes Therapy Afrezza 6/27/2014 2:29:22 PM
    MannKind Corporation (MNKD) Drops As The FDA Delays Decision On Inhaled Insulin Treatment 4/7/2014 7:39:18 AM
    MannKind Corporation (MNKD) Rockets As FDA Panel Backs Inhaled Diabetes Drug Afrezza; Stock Up 73.88% At Market Close (April 2, 2014) 4/2/2014 7:58:18 AM
    FDA Staff Raises Questions About MannKind Corporation (MNKD) Diabetes Device 3/28/2014 7:45:43 AM
    MannKind Corporation (MNKD) to Present at Canaccord Genuity Medical Technologies & Diagnostics Forum 11/8/2013 8:52:10 AM
    MannKind Corporation (MNKD) Announces FDA Acknowledgement of Resubmission of New Drug Application for AFREZZA 10/30/2013 7:39:42 AM
    MannKind Corporation (MNKD) to Hold 2013 Third Quarter Financial Results Conference Call on November 4, 2013 10/29/2013 7:02:54 AM
    12345678910...
    //-->